Cargando…

Corrigendum to: The long noncoding RNA HORAS5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional program

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998384/ https://www.ncbi.nlm.nih.gov/pubmed/32017425 http://dx.doi.org/10.1002/1878-0261.12618

Ejemplares similares

The long noncoding RNA HORAS5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional program
por: Parolia, Abhijit, et al.
Publicado: (2019)

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]
Publicado: (2019)

Combination of phospholipase Cε knockdown with GANT61 sensitizes castration-resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway
por: Sun, Wei, et al.
Publicado: (2022)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study [Corrigendum]
Publicado: (2018)

Corrigendum to ‘New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells’
por: Lee, Soo Ok, et al.
Publicado: (2020)

LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer
por: Zhang, Ali, et al.
Publicado: (2015)

Long noncoding RNA-mediated activation of androgen receptor in prostate cancer
por: Petrovics, Gyorgy, et al.
Publicado: (2014)

Corrigendum to “Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy”
por: Neubecker, Katherine, et al.
Publicado: (2017)

Long noncoding RNA: noncoding and not coded
por: Toiber, Debra, et al.
Publicado: (2017)

Corrigendum to “Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States”
por: Saltus, Catherine W., et al.
Publicado: (2019)

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum]
Publicado: (2021)

Regulation of the androgen receptor by SET9-mediated methylation
por: Gaughan, Luke, et al.
Publicado: (2013)

Corrigendum to “The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer”
por: Al-Shamsi, Humaid O., et al.
Publicado: (2017)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Corrigendum to “Genome-Wide Identification of Long Noncoding RNAs in Human Intervertebral Disc Degeneration by RNA Sequencing”
por: Zhao, Bo, et al.
Publicado: (2019)

Correction to ‘BAP18 coactivates androgen receptor action and promotes prostate cancer progression’
por: Sun, Shiying, et al.
Publicado: (2021)

Corrigendum to “The Effect of Botulinum Toxin Type A on Expression Profiling of Long Noncoding RNAs in Human Dermal Fibroblasts”
por: Miao, Ying-Ying, et al.
Publicado: (2019)

Corrigendum to Long Noncoding RNA PTTG3P Expression Is an Unfavorable Prognostic Marker for Patients With Hepatocellular Carcinoma
Publicado: (2020)

Corrigendum to “Prognostic Effect of Long Noncoding RNA NEAT1 Expression Depends on p53 Mutation Status in Cancer”
por: Idogawa, Masashi, et al.
Publicado: (2019)

Long Noncoding RNA LINC00460 Facilitates Colorectal Cancer Progression by Negatively Regulating miR-613 [Corrigendum]
Publicado: (2021)

Registered report: the androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man
por: Chronscinski, Denise, et al.
Publicado: (2015)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer
Publicado: (2023)

Correction to ‘Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation’
por: Gaughan, Luke, et al.
Publicado: (2021)

Long Noncoding RNA GAS5 Acts As A Tumor Suppressor In Laryngeal Squamous Cell Carcinoma Via miR-21 [Corrigendum]
Publicado: (2019)

Corrigendum to “Long Noncoding RNA LINC00460 Promotes Cell Progression by Sponging miR-4443 in Head and Neck Squamous Cell Carcinoma”
Publicado: (2021)

Corrigendum to “Long Noncoding RNA TUG1/miR-29c Axis Affects Cell Proliferation, Invasion, and Migration in Human Pancreatic Cancer”
por: Lu, Yebin, et al.
Publicado: (2021)

Corrigendum to “Circadian Control of Global Transcription”
por: Li, Shujing, et al.
Publicado: (2016)

Corrigendum to “GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)”
Publicado: (2022)

Androgen Receptor-Mediated Transcription in Prostate Cancer
por: Özturan, Doğancan, et al.
Publicado: (2022)

Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2017)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Publicado: (2014)

Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription
por: Jia, Lin, et al.
Publicado: (2018)

HepaCAM inhibits cell proliferation and invasion in prostate cancer by suppressing nuclear translocation of the androgen receptor via its cytoplasmic domain
por: Deng, Qingfu, et al.
Publicado: (2022)

Synergistic Effect Of A Retinoid X Receptor-Selective Ligand Bexarotene And Docetaxel In Prostate Cancer [Corrigendum]
Publicado: (2019)

Long Noncoding RNA H19 Facilitates Small Cell Lung Cancer Tumorigenesis Through miR-140-5p/FGF9 Axis [Corrigendum]
Publicado: (2020)

Corrigendum to “Different Effects of Myoinositol plus Folic Acid versus Combined Oral Treatment on Androgen Levels in PCOS Women”
por: Ozay, Ali Cenk, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n391dgb9buu0386d4lp2dgs4vs